Journal of
Molecular Biology and Drug Design

Review Article Open Access

Current Clinical Management of Preeclampsia

Gudisa Bereda[1*]

[1]Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia.

[*]**Corresponding Author:** Gudisa B, Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia. E-mail: gudisabareda95@gmail.com

Citation: Bereda G. Current Clinical Management of Preeclampsia. Journal of Molecular Biology and Drug Design. 2022;1(1):1-6.

Received Date:2nd February,2022 **Accepted Date:30th March,2022** **Published Date:7th April,2022**

Abstract

Preeclampsia that affects three to five percent of all pregnancies is delineated as fresh onset hypertension and proteinuria happening after twenty weeks gestation. Preeclampsia is usually related with maternal and neonatal morbidity and mortality. Availability of obesity, smoking, psychological stress, chronic kidney disease, polycystic ovarian disease, and PAI-1 polymorphism were similarly consociated with preeclampsia. Preeclampsia is described by placental hypoxia and/or ischemia, excessive oxidative stress, in consociation with endothelial dysfunction. Preeclampsia is diagnosed in women presenting with fresh onset hypertension and proteinuria during the second half of pregnancy. Recently the chief treatment for preeclampsia is to render the baby as soon as he/she is consummate prudent to accelerate maternal and fetal wellbeing. Prophylaxis against maternal seizures (eclampsia) is achieved by the usage of magnesium sulfate. Magnesium sulfate is administered either as an intravenous bolus or intramuscular injection.

Keywords: Clinical Management; Current; Preeclampsia

Introduction

Preeclampsia is a multi-system disorder of pregnancy, which is described by fresh onset of HTN (systolic and diastolic blood pressure of ≥ 140- and 90-mm Hg, respectively, on 2 occasions, at least six hrs apart) and proteinuria (protein excretion of ≥ 300 mg in a twenty-four hrs urine collection, or a dipstick of ≥ 2^{+}), that advance after twenty weeks of gestation in formerly normotensive women [1-3]. The International Society for the survey of HTN in Pregnancy delineates preeclampsia as hypertension of at least 140/90 mmHg on 2 separate occasions four hrs apart accompanied by important proteinuria of at least 0.3 g in a twenty-four hrs collection of urine (or greater than 30 mg/mmol protein/creatinine ratio), arising de novo after the 20th week of gestation in a formerly normotensive woman and resolving completely by the 6th postpartum week [4, 5]. Preeclampsia is ubiquitously classified into 2 clinically distinct phenotypes based on the gestation of onset and the severity of the condition. Preeclampsia diagnosed before thirty-four weeks' gestation or requiring delivery before 37 weeks' gestation is often labeled as early-onset disease, whereas the remainder is referred to as late-onset disease. The indication between early-onset and late-onset diseases is reflected in the prevalence of adverse maternal outcomes, which is approximately 10% for late and 15% for the early-onset variants [6, 7]. Preeclampsia that influences three to five percent of entire pregnancies is delineated as fresh onset hypertension and proteinuria happening after twenty weeks gestation [8, 9]. Preeclampsia is usually

Journal of
Molecular Biology and Drug Design

Review Article Open Access

related with maternal and neonatal morbidity and mortality. Preterm render and growth retardation are the consummate ubiquitous adverse effects of preeclampsia. On the other hand, preeclampsia perhaps advances to severe preeclampsia or eclampsia, which is attributed to higher rate of stillbirth [10, 11].

Risk Factors of Preeclampsia

Preeclampsia and CVDs share genetic and non-genetic peril factors. Availability of obesity, smoking, psychological stress, CKD, polycystic ovarian disease, and PAI-1 polymorphism were similarly consociated with preeclampsia [12]. The increased risk may be due either to the change in paternity or to an increased inter-pregnancy interval. Additionally, women with a history of preeclampsia in a prior pregnancy are at elevated pitfall of developing preeclampsia in future pregnancies, specifically if the preeclampsia had advanced early in gestation [13-15]. High-risk women involve those who have past history of HTN, CKD, insulin-dependent diabetics, and women with former early onset preeclampsia [4, 16].

Pathophysiology of Preeclampsia

Preeclampsia is described by placental hypoxia and/or ischemia, extreme oxidative stress, in consociation with endothelial dysfunction. Normal pregnancy induces alters in maternal physiology to make fit the fetus and the placenta, as well as produced from the fetoplacental unit, such as, placental exosomes, microparticles, and microchimeric cells. In regular pregnancy, there is a change towards a Th2-type immune reaction which defends the baby from a Th1- type (cytotoxic) reaction which could detriment the baby with its products like interleukin-2, IL-12, interferon γ (IFNY), and tumor necrosis factor α (TNFα). Thus, inflammation seems to be the link between the adaptive immune reaction and the recurrence of preeclampsia. Systemic inflammation in preeclampsia seems to favor a major of Th1- type reaction. The improper vascular remodeling and a hypo perfused placenta, which sequence from the shallow cytotrophoblast migration toward the uterine spiral arterioles, have been described as significant inducing events in preeclampsia. The placenta becomes ischemic which influences to the loose of factors that are consociated with maternal vascular endothelial dysfunction. Endothelial malfunction has been a frequent phenotype of preeclampsia and it is described by vasoconstriction and decreased blood flow to organs. Furthermore, comorbid conditions such as diabetes and obesity render to factors released from the ischemic placenta. In addition, an increase in immune cells and inflammatory cytokines are related to endothelial dysfunction during preeclampsia. Significantly, pivotal such as endothelin-1 (ET-1), anti-angiogenic factor Fms-like tyrosine kinase 1 (sFlt-1), agonistic autoantibodies to the angiotensin II type I receptor (AT1-AA) and reduced nitric oxide (NO) have been reveal to play an indispensable function in the advancement of preeclampsia [17-24].



Figure 1: Pathogenesis of endothelial dysfunction, hypertension, and edema with preeclampsia

Clinical manifestations and Diagnostic Criteria

Preeclampsia is a heterogeneous situation that can be challenging to diagnose, given the broad spectrum of presentation and the recent dearth of a robust diagnostic test. The cardinal features of preeclampsia are fresh-onset hypertension (defined as systolic BP ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) and proteinuria (300 mg or greater in a twenty-four hrs urine specimen). With the classical presentation, women typically advance preeclampsia after twenty weeks gestation and prior to forty-eight hrs postpartum. A percentage of women available atypically without one of these cardinal signs, making the diagnosis sophisticate to attest or exclude. Up to 20% of women

Journal of
Molecular Biology and Drug Design
Bereda G, J. et al. Mol. Biol. Drug Des. 2022, 1:1
Review Article
Open Access

with atypical preeclampsia have minimal or no-proteinuria. The level of proteinuria in preeclampsia perhaps different from minimal to nephrotic; however, the amount of proteinuria does not seem to influence maternal or fetal consequences [25]. Preeclampsia is diagnosed in women coming with new onset hypertension and proteinuria during the second half of pregnancy [26, 27].

Management

Recently the chief treatment for preeclampsia is to render the baby as soon as he/she is most prudent to accelerate maternal and fetal wellbeing. Effective treatment of preeclampsia perhaps classified into three classifications; prevention of preeclampsia, early detection, and management. Women thought-out to be at high peril of preeclampsia (such as those with chronic hypertension, coexisting renal disease, or antiphospholipid syndrome should be referred for pre-pregnancy counseling to distinguish modifiable peril factors) [4]. Recognition and treatment of persistently increased (greater than fifteen minutes in duration) severe hypertension is necessary to prevent maternal and fetal morbidity and mortality. The goal of management is to reduce maternal blood pressure 15–25%, with an aim SBP of 140–150 mmHg and DBP of 90–100 mmHg. Care is given to prohibit extreme decreasing of BP, as this perhaps farther decrease placental perfusion and potentiate negative consequences on fetal status [28]. Pharmacological intervention aimed at restoring the angiogenic balance may prevent or modify the course of preeclampsia.

Magnesium sulfate: Prophylaxis against maternal seizures (eclampsia) is achieved by the usage of magnesium sulfate. Magnesium sulfate is administered either as an intravenous bolus or intramuscular injection. While magnesium sulfate perhaps has the suitable outcome of decreasing maternal blood pressure, it has been revealed to be superior to distinctive anticonvulsants in the prevention of eclamptic seizures and is thought-out 1st-line therapy. A loading dose of 4 g of MgSO4 is given, followed by a maintenance infusion of 1 g/hour, generally for 24 hours after delivery. A documented medical assessment should happen at four hourly intervals and all patients should have continuous pulse oximetry, hourly assessment of urine output and respiratory rate, and reflexes checked every four hrs [29]. Patients with preeclampsia are frequently managed with magnesium for twenty-four hrs to reduce the likelihood of eclampsia. Magnesium sulfate also normalizes placental interlekin-6 synthesis in a model of preeclampsia, which helps the fact that certain of its con perhaps drive from anti-inflammatory actions.

Fluid management: Fluid management should be closely monitored, as these patients have a decreased plasma volume and are at elevated peril of pulmonary edema. Total input should not exceed 80 mL/hour (approximately 1 mL/kg/hour). Oxytocin, if necessitated, should be used at high concentrations and involved as part of the total fluid input. Oliguria should not precipitate any individual intervention, save to encourage early delivery [4].

Aspirin: Since inflammation seems to play an indispensable function in the pathophysiology of preeclampsia, certain researchers have discussed the function of aspirin in prevention and treatment of preeclampsia [30]. Advantages from aspirin in prevention of preeclampsia and its vascular complication perhaps derive not just from an anti-inflammatory action but from a putative outcome of restoring the balance between thromboxane and prostacyclin in the vasculature.

Calcium: Calcium supplementation (one gram/day) is consociated with an important decrement in the pitfall of preeclampsia, specifically for women with low-calcium diets [31]. Calcium supplementation did not de-escalate the incidence of preeclampsia; it appeared to reduce adverse outcomes in women who developed preeclampsia.

Antihypertensive therapy: The intention of antihypertensive management is to lower blood pressure to less than 160/105 mmHg (mean arterial pressure less than 125 mmHg). Blood pressure perhaps drops suddenly on begging of management; thereupon, dosage should be titrated gradually to avoid affecting uteroplacental circulation, which perhaps sequence in

Journal of
Molecular Biology and Drug Design
Bereda G, J. et al. Mol. Biol. Drug Des. 2022, 1:1
Review Article
Open Access

fetal distress. Labetalol (a beta-blocker) and/or hydralazine (a vasodilator) are thought-out 1st-line treatment for acute hypertensive emergency and are administered intravenously as a bolus. Immediate-release oral nifedipine, a calcium channel blocker, perhaps used as 1st-line treatment, particularly when intravenous access is not present [32].

Nitric oxide: Since preeclampsia is consociated with decreased secretion of vasodilators and elevated secretion of vasoconstrictors, researchers have sought to investigate possible therapeutic advantage for use of NO donors in management and prevention of preeclampsia. Animal data have revealed that chronic nitric oxide blockade is consociated with hypertension, proteinuria, and decrements in kidney function [33, 34].

Prevention of Stroke in women with preeclampsia: Aspirin is an indispensable prevention technique for ischemic stroke in women. Interestingly, it has also been used for prevention of preeclampsia; thereupon prevention with aspirin represents another overlap between stroke and preeclampsia disorders. There was an important reduction in the rate of preeclampsia with low dose aspirin started at sixteen weeks gestation or earlier in women identified as moderate or high risk. The rate of intrauterine growth restriction was reduced to a similar degree. Since the rate of severe preeclampsia was also reduced, cerebrovascular complications would also theoretically be reduced as well.



Figure 2: schematic illustrations of preeclampsia management algorithm

Complications

Potential fetal complications include low birth weight, prematurity and death. Maternal complications involve RF, HELLP syndrome (hemolysis, elevated liver enzymes, and thrombocytopenia), liver failure, cerebral edema with seizures and rarely death [35].

Conclusion

Preeclampsia is a disease of pregnancy described by HTN and proteinuria advancing after twenty weeks of gestation. It has been estimated that five to seven percent of pregnancies worldwide are complicated by this disorder sequencing in a very large disease burden. Preeclampsia is a leading antecedent of maternal and fetal morbidity and mortality. A novel peril factor for preeclampsia perhaps migraine. Anomalous placentation and maternal vascular remodeling affect to placental under perfusion, hypoxia, and/or oxidative stress, with placental release of factors which antecedent the second stage of endothelial dysfunction and distinctive manifestations of preeclampsia. The focuses of clinical treatment of preeclampsia are inhibition of maternal morbidity by aggressive management of hypertensive emergency, maternal seizure inhibition in solemn preeclampsia, and limiting detriment to the fetus. Magnesium sulfate is the consummate effective agent in inhibition of eclampsia in women with preeclampsia. It has antiseizure effects as well as a being a vasodilator.

Abbreviations

BP: Blood pressure; CKD: Chronic kidney disease; CVDs: Cardiovascular diseases; DBP: Diastolic blood pressure; HELLP syndrome: Hemolysis, elevated liver enzymes, and thrombocytopenia; MgSO4: Magnesium sulfate; NO: Nitric oxide; SBP: Systolic blood pressure

Acknowledgement

The author would be grateful to anonymous reviewers for the comments that increase the quality of this manuscript.

Data Sources: Sources searched include Google Scholar, Research Gate, PubMed, NCBI, NDSS, PMID, PMCID, Scopus database, Scielo and Cochrane database. Search terms included: clinical management

Journal of
Molecular Biology and Drug Design

Review Article Open Access

of preeclampsia.

References

1. Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S, Lapaire O. Potential markers of preeclampsia–a review. Reproductive biology and endocrinology. 2009 Dec;7(1):1-4.

2. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005 Jun 10;308(5728):1592-4.

3. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. The Lancet. 2005 Feb 26;365(9461):785-99.

4. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integrated blood pressure control. 2015; 8:7.

5. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. The Lancet. 2010 Aug 21;376(9741):631-44.

6. Kalafat E, Thilaganathan B. Cardiovascular origins of preeclampsia. Current Opinion in Obstetrics and Gynecology. 2017 Dec 1;29(6):383-9.

7. von Dadelszen P, Payne B, Li J, Ansermino JM, Pipkin FB, Côté AM, Douglas MJ, Gruslin A, Hutcheon JA, Joseph KS, Kyle PM. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. The Lancet. 2011 Jan 15;377(9761):219-27.

8. Naljayan MV, Karumanchi SA. New developments in the pathogenesis of preeclampsia. Advances in chronic kidney disease. 2013 May 1;20(3):265-70.

9. Program NH. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. American journal of obstetrics and gynecology. 2000 Jul 1;183(1): s1-22.

10. Altınbas S, Toğrul C, Orhan A, Yücel M, Danısman N. Increased MPV is not a significant predictor for preeclampsia during pregnancy. Journal of clinical laboratory analysis. 2012 Sep;26(5):403-6.

11. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening G. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007 Aug 2;357(5):462-9.

12. Davis EF, Lewandowski AJ, Aye C, Williamson W, Boardman H, Huang RC, Mori TA, Newnham J, Beilin LJ, Leeson P. Clinical cardiovascular risk during young adulthood in offspring of hypertensive pregnancies: insights from a 20-year prospective follow-up birth cohort. BMJ open. 2015 Jun 1;5(6): e008136.

13. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annual Review of Pathology: Mechanisms of Disease. 2010 Feb 28; 5:173-92.

14. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstetrics & Gynecology. 2008 Aug 1;112(2):359-72.

15. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Bmj. 2005 Mar 10;330(7491):565.

16. National Collaborating Centre for Women's and Children's Health (UK. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy.

17. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005 Dec 1;46(6):1243-9.

18. Granger JP. Inflammatory cytokines, vascular function, and hypertension. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2004 Jun;286(6): R989-90.

Journal of
Molecular Biology and Drug Design

Review Article Open Access

19. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002 Jan 1;9(3):147-60.

20. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert reviews in molecular medicine. 2006 Jan;8(3):1-20.

21. Redman CW, Sargent IL. Immunology of pre-eclampsia. American journal of reproductive immunology. 2010 Jun;63(6):534-43.

22. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. InSeminars in fetal and neonatal medicine 2006 Oct 1 (Vol. 11, No. 5, pp. 309-316). WB Saunders.

23. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Current hypertension reports. 2007 Dec;9(6):480-5.

24. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1–induced hypertension in pregnant rats. Hypertension. 2010 Feb 1;55(2):394-8.

25. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. American journal of obstetrics and gynecology. 2009 May 1;200(5):481-e1.

26. Weissgerber TL, Mudd LM. Preeclampsia and diabetes. Current diabetes reports. 2015 Mar;15(3):1-0.

27. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' task force on hypertension in pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31.

28. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. The lancet. 2006 Apr 1;367(9516):1066-74.

29. LaMarca B, Brewer J, Wallace K. IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulphate?. International journal of interferon, cytokine and mediator research: IJIM. 2011 Jul 1;2011(3):59.

30. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet. 2007 May 26;369(9575):1791-8.

31. Too GT, Hill JB. Hypertensive crisis during pregnancy and postpartum period. InSeminars in Perinatology 2013 Aug 1 (Vol. 37, No. 4, pp. 280-287). WB Saunders.

32. Rossi AC, Mullin PM. Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011 Sep 1;158(1):9-16.

33. Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J, De Greeff A, Poston L, Shennan A, WHO Vitamin C and Vitamin E Trial Group. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG: An International Journal of Obstetrics & Gynaecology. 2009 May;116(6):780-8.

34. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvascular research. 2008 Jan 1;75(1):1-8.

35. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertension in pregnancy. 2003 Jan 1;22(2):203-12.